ICER plans to assess the comparative clinical effectiveness and value of nadofaragene firadenovec (Adstiladrin®, FKD Therapies Oy and FerGene) for the treatment of bladder cancer. Nadofaragene firadenovec has received a fast track and breakthrough therapy designation from the FDA, with an anticipated decision expected in mid-2020.
Review date: November 2020
For more information, please contact Maggie O’Grady, Program Manager, at email@example.com.
The Midwest CEPAC will convene virtually to deliberate and vote on evidence presented in ICER's report on digital therapeutics for bladder cancer.